Abbott Laboratories Management maybe Sizing up ( Amex: RNN ) Rexahn with a nice Robust Drug Pipeline that Teva and Pfizer like so much. Rexahn right now can be bought for pennies on the dollar.
Rexahn Potential is so huge it may be better and than the biggest Mega Lotto Jackpot in History.... Maybe biggest Biotech Discovery in Years.
Buy ABT with your Dollars and RNN with your spare pocket change. Pocket Change may Grow to many ( RNN ) Rexahn Dollars.
Teva likes RX 3117 Cancer Drug so much it partner with Rexahn and bought 6% of RNN shares.
Pfizer I am believe likes Rexahn's ED Drug Zoraxel in Phase llb Clinical Trail if everything goes well with Zoraxel Phase llb then my bet is Pfizer will make a deal with Rexahn for Hundreds of Millions of Upfront Dollars or just buy All of Rexahn for a New Drug that will replace Viagra in the future, that Drug is Zoraxel.
ED Drug Zoraxel if Approved by FDA has a MultiBillion Dollar Potential ... 3 to 15 Billion Dollars in sales per year.. On the Rexahn Board right now is a guy from Pfizer for 28 Plus Years named Peter Brandt. Rockville, MD, September 13, 2010 Rexahn Pharmaceuticals Announces the Appointment of Peter Brandt and Richard Kivel to Board of Directors
Peter Brandt was most recently President and Chief Executive Officer of Noven Pharmaceuticals, a specialty pharmaceutical company based in Miami, Florida. Prior to leading Noven, Brandt spent 28 years at Pfizer, the world’s largest pharmaceutical company. He served as Pfizer’s President – U.S. Pharmaceuticals Operations, where he helped deliver revenue and earnings growth while engineering major change within Pfizer’s U.S. pharmaceuticals organization. Prior to running the U.S. operations, he led the Latin American Pharmaceuticals Operations, as well as the following Pfizer Worldwide Pharmaceuticals functions: Finance, Information Technology, Planning and Business Development. He also oversaw the operations of Pfizer’s care management subsidiary, Pfizer Healthcare Solutions.
Today, our clinical pipeline features multiple Phase II drugs that we believe will fill a void of viable therapies for diseases where a meaningful cure is overdue. Serdaxin® a best-in-class therapy for treating depression, and potentially Parkinson’s Disease and Alzheimer’s Disease. Zoraxel™ a first-in-class CNS-based therapy for treating sexual dysfunction. Archexin® a first-in-class AKT-inhibitor therapy for treating various cancers, such as pancreatic cancer, renal cell carcinoma (RCC), glioblastoma, and cancers of the ovary and stomach.
These lead clinical drugs are part of a robust pipeline that includes several promising pre-clinical anti-cancer compounds. Our strategy is to continue building a significant product pipeline of innovative medicines that we will commercialize alone or with pharma partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating bio-pharmaceutical company – one with the expertise to develop cures for the major diseases of our time.
RNN For Pocket Change is a buy ABT for Dollars is a Strong Buy in my Humble Opinion
( Amex: RNN ) Rexahn with a nice Robust Drug Pipeline that Teva and Pfizer like so much. Rexahn right now can be bought for pennies on the dollar. Yes indeed, Zoraxel is the drug I am waiting for because they say it will be better than viagra and all the rest of the ED drugs on the market today. Don't Worry Pfizer or other will buy this Penny Biotech for mucho Bucks Soon.
Zoraxel is still far away and will not be able to compete the ED battle.
Abbott will start marketing by mid-2012 the ED treatment VITAROS in Canada from Apricus Bio (APRI). VITAROS will replace the PDE5 drugs (Viagra, Cialis, Levitra, etc.) as the ED product of choice since it only takes effect in 5 minutes and has no side-effects like the PDE5 drugs (loss vision, heart problem, etc.).
VITAROS will be marketed in Germany by Sandoz (a division of Novartis), in Italy by Bracco, in the Middle East/Israel by Elis Pharm. and Neopharm, , and in the US by Warner Chilcott. More partners will be forthcoming for Asia, South America, and the rest of the world.
Buy APRI before it rockets. It has very robust pipeline. Other products are FEMPROX, the leading female sexual arousal disorder treatment, MYCOVA, PreVonco, and a host of oncology treatment. All of their products work on their proprietary proven NexACT drug delivery system technology.